Company news
Livzon Pharmaceutical Group, Inc. Class A (SZSE:000513) news
Livzon Pharmaceutical Group, Inc. Class A news releases on 6ix. Latest, Aug 22, 2023: Livzon Pharmaceutical : Interim Report 2023
Press releases & updates
Livzon Pharmaceutical : Interim Report 2023
August 22, 2023
Livzon Pharmaceutical : Interim Report 2022
August 9, 2022
Livzon Pharmaceutical : 2022 FIRST QUARTERLY REPORT
April 21, 2022
Livzon Pharmaceutical : was recognized as the National Enterprise Technology Center with High Scores
April 20, 2022
Livzon Pharmaceutical : A Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed and manufactured by Livzon has shown good protective effects against the Omicron variant in a phase III clinical booster trial
April 20, 2022
Livzon Pharmaceutical : Rapid Test for 2019-nCoV-2 Antigen (Lateral Flow) approved by China NMPA.
April 20, 2022
V-01 as a Sequential Booster Can Produce Good Protection against Omicron ---- Latest Phase III Data of COVID-19 Vaccine by Livzon Pharma
February 18, 2022
Livzon Pharmaceutical : ANNOUNCEMENT ON PROGRESS OF THE REORGANIZATION
May 12, 2021
Livzon Pharmaceutical : VOLUNTARY ANNOUNCEMENT LAUNCH OF FUTURES HEDGING ACTIVITIES BY CONTROLLING SUBSIDIARIES
May 6, 2021
Livzon Pharmaceutical : CANCELLATION OF THE REPURCHASED H SHARES
May 6, 2021
Livzon Pharmaceutical : VOLUNTARY ANNOUNCEMENT UPDATE ANNOUNCEMENT ON ACQUISITION OF 40.00% EQUITY INTEREST IN TIANJIN TONGRENTANG
April 27, 2021
Livzon Pharmaceutical : PROPOSED COMPANY'S PROVISION OF FINANCING GUARANTEES TO CONTROLLING SUBSIDIARY LIVZON MAB
April 15, 2021
Livzon Pharmaceutical : PROPOSED ADOPTION OF THE FIRST PHASE OWNERSHIP SCHEME (DRAFT) AND ITS ADMINISTRATIVE MEASURES UNDER THE MEDIUM TO LONG-TERM BUSINESS PARTNER SHARE OWNERSHIP SCHEME
April 14, 2021
Livzon Pharmaceutical : CONNECTED TRANSACTION IN RELATION TO GRANT OF SUBSCRIPTION TO CONNECTED PERSONS PURSUANT TO THE PROPOSED FIRST PHASE OWNERSHIP SCHEME
April 8, 2021